On 14 November 2024, the European Medicines Agency (EMA) granted marketing authorisation for mirvetuximab soravtansine (Elahere), intended for the treatment of adults with FRα-positive epithelial ovarian, Fallopian tube and primary peritoneal cancer [8]. This evidence concerns the gene FOLR1 and peritoneum cancer.